Target the nerve. Relieve the pain.

Olfax Medical develops therapeutics for patients living with trigeminal-mediated pain — the primary headache disorders and chronic facial pain conditions rooted in the trigeminal nerve. Our lead program, OFX-001, targets this pathway directly, giving patients a way to stop an attack without the delay, side effects, or dependency risk of systemic treatment.

Cluster headache, migraine, post-traumatic headache, and trigeminal neuralgia look different in the clinic, but they share a common driver: the trigeminal nerve and its role in transmitting and amplifying facial and head pain. Treatments that reach this pathway directly — rather than circulating through the bloodstream — can act faster and more selectively, with fewer of the side effects associated with oral or systemic therapy.

OFX-001 is a targeted intranasal drug-device combination product in clinical development for the acute treatment of cluster headache and refractory migraine.